EXCiPACT Signs Agreements with Certification Bodies to Undertake Certified Audits of Pharmaceutical Excipient Suppliers

EXCiPACT Signs Agreements with Certification Bodies to Undertake Certified Audits of Pharmaceutical Excipient Suppliers

English
1 Page
Read
Download
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

EXCiPACT Signs Agreements with Certification Bodies to Undertake Certified Audits of Pharmaceutical Excipient Suppliers PR Newswire BRUSSELS, December 5, 2012 BRUSSELS, December 5, 2012 /PRNewswire/ -- The EXCiPACT Association - a project of the IPEC Federation - is pleased to

Subjects

Informations

Published by
Reads 14
Language English
Report a problem
EXCiPACT Signs Agreements with Certification Bodies to Undertake Certified Audits of Pharmaceutical Excipient Suppliers
PR Newswire BRUSSELS, December 5, 2012
BRUSSELS,December 5, 2012/PRNewswire/ --
The EXCiPACT Association - a project of the IPEC Federation - is pleased to announce that it has completed Framework Agreements with two internationally-recognised Certification Bodies (CBs) for the certification of the [TM] manufacture and distribution of pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practices (GMP) and Good Distribution Practices (GD P) Certification Standards. The CBs are mdc medical device [1] [2] certification GmbH / blue inspection body GmbH and SGS .
Auditors employed by these organisations who have completed the formal EXCiPACT Training Programme will now undertake EXCiPACT-witnessed pilot audits of pharmaceutical excipient suppliers. The independent witnesses will allow EXCiPACT to verify that the standards and the auditor training have been defined and implemented correctly. Once each auditor has been assessed satisfactorily then they will become a fully qualified Certified Auditor under [TM] the EXCiPACT Certification Scheme.
The EXCiPACT Scheme has been made available at a time when the regulators in the EU andUSA require the holder of the marketing authorization for medicines to ensure that appropriate GMP and GDP is applied to the manufacture and distribution of both APIs and excipients. The requirement for site audit by FDA and EMA continues to be pressed for pharmaceutical excipients and as a result their suppliers must be prepared to receive increasing numbers of audits. EXCiPACT Certification can help to avoid some of these additional audits in a cost-effective manner. EXCiPACT expects to register other Certifying Bodies and Auditors in the near future.
Notes for the Editor
EXCiPACT is a project of the IPEC Federation, a global organization to promote quality in pharmaceutical excipients. (seehttp://www.ipecfed.org). EXCiPACT is a voluntary international scheme to provide for independent 3rd party certification of manufacturers, suppliers and distributors of pharmaceutical excipients worldwide. It will ensure patient safety through supplier quality while minimising the overall costs for assessing the excipient supply chain. It was launched inJanuary 2012ong pharmaceuticalsince when there has been considerable interest am excipient suppliers, customers and regulators. For further information seehttp://www.excipact.orgor contact info@excipact.org.
References
1 & 2: For further information about mdc medical device certification GmbH /blue inspection body GmbH and SGS seehttp://www.mdc-ce.de/index_en.htm,http://www.blue-inspection.com andhttp://www.sgs.comrespectively.